Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194713 | 0.93 | HTR6 (0.51) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2195199 | 0.87 | MEN1 (0.46) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2198404 | 0.86 | HTR2A (0.60) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2197413 | 0.86 | HTR6 (0.44) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2194333 | 0.83 | SLC40A1 (0.47) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2194230 | 0.82 | AKT1 (0.42) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2198396 | 0.82 | HTR2A (0.46) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL951404 | 0.82 | HTR6 (0.56) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL11956740 | 0.82 | HTR6 (0.56) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3206061 | 0.82 | HTR2A (0.56) | HTR6HTR2AHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
| WO-2021102370-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-05-27 | — | — | WO | disclosed |
| EP-2185555-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2016-03-16 | — | — | EP | disclosed |
| CN-101687866-B | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO KG | 2014-06-04 | — | — | CN | disclosed |
| US-8440694-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20130005703-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8293913-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8236947-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | disclosed |
| US-20110237792-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED | 2011-09-29 | — | — | US | disclosed |
| US-20070032504-A1 | Polymorphic form of 3-phenylsulfonyl -8-piperazin-1-yl-quinoline | ROIVANT NEUROSCIENCES LTD. (BM) | 2007-02-08 | — | — | US | disclosed |
| US-20060287334-A1 | Quinoline compounds and pharmeceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1667975-A1 | A POLYMORPHIC FORM OF 3-PHENYLSULFONYL-8-PIPERAZIN-1-YL-QUINOLINE | GLAXO GROUP LIMITED (GB) | 2006-06-14 | — | — | EP | disclosed |
| EP-1663980-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| CN-1656075-A | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | CN | disclosed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | disclosed |
| WO-2005040124-A1 | A POLYMORPHIC FORM OF 3-PHENYLSULFONYL -8-PIPERAZIN-1-YL-QUINOLINE | GLAXO GROUP LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005026125-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | HTR6 111/4885HTR2A 124/4885HTR1A 132/4885 |
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | HTR6 4434/4885HTR2A 4707/4885HTR1A 4795/4885 |
| US-20130005703-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR | HTR6, HTR1A, HTR3B | HTR6 1/4885HTR2A 7/4885HTR1A 2/4885 |
| US-20110237792-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR7 | HTR6 1/4885HTR2A 8/4885HTR1A 2/4885 |
| US-20060287334-A1 | Quinoline compounds and pharmeceutical compositions containing them | ATP6V1B2, CNR2, CNR1 | HTR6 43/4885HTR2A 84/4885HTR1A 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.